Cargando…
Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298006/ https://www.ncbi.nlm.nih.gov/pubmed/34303433 http://dx.doi.org/10.1016/S0140-6736(21)01422-7 |
| _version_ | 1783725971891814400 |
|---|---|
| author | Horby, Peter Staplin, Natalie Haynes, Richard Landray, Martin |
| author_facet | Horby, Peter Staplin, Natalie Haynes, Richard Landray, Martin |
| author_sort | Horby, Peter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8298006 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82980062021-07-23 Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply Horby, Peter Staplin, Natalie Haynes, Richard Landray, Martin Lancet Correspondence Elsevier Ltd. 2021 2021-07-22 /pmc/articles/PMC8298006/ /pubmed/34303433 http://dx.doi.org/10.1016/S0140-6736(21)01422-7 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Horby, Peter Staplin, Natalie Haynes, Richard Landray, Martin Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply |
| title | Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply |
| title_full | Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply |
| title_fullStr | Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply |
| title_full_unstemmed | Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply |
| title_short | Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply |
| title_sort | tocilizumab in covid-19 therapy: who benefits, and how? – authors' reply |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298006/ https://www.ncbi.nlm.nih.gov/pubmed/34303433 http://dx.doi.org/10.1016/S0140-6736(21)01422-7 |
| work_keys_str_mv | AT horbypeter tocilizumabincovid19therapywhobenefitsandhowauthorsreply AT staplinnatalie tocilizumabincovid19therapywhobenefitsandhowauthorsreply AT haynesrichard tocilizumabincovid19therapywhobenefitsandhowauthorsreply AT landraymartin tocilizumabincovid19therapywhobenefitsandhowauthorsreply |